(Q40176032)

18 September 2017

title

Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma (English)

1 reference

18 September 2017

1 reference

1 reference

18 September 2017

Hisashi Imai

1 reference

18 September 2017

Masanao Saio

1 reference

18 September 2017

Kenichi Nonaka

1 reference

18 September 2017

Tatsuhiko Suwa

1 reference

18 September 2017

Guan-Feng Ouyang

1 reference

18 September 2017

Jiro Nakagawa

1 reference

18 September 2017

Hiroyuki Tomita

1 reference

18 September 2017

Shinji Osada

1 reference

18 September 2017

Yasuyuki Sugiyama

1 reference

18 September 2017

Yosuke Adachi

1 reference

18 September 2017

Tsuyoshi Takami

1 reference

18 September 2017

publication date

1 March 2007

1 reference

18 September 2017

1 reference

18 September 2017

1 reference

18 September 2017

1 reference

18 September 2017

page(s)

416-423

1 reference

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Structure and expression of a cloned cDNA for human interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon c

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Human CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

CD4+CD25+-regulatory T cells from mouse to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

CD25+CD4+ T cells contribute to the control of memory CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Vascular leak syndrome: a side effect of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00385.X

10.1111/J.1349-7006.2006.00385.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference